Contact Us

The choice depends on whether you are studying PD-L1 in a high-transfection-efficiency biochemistry platform for systematic structure-function and PD-L1-targeted compound development. The Knockout line is the standard tool for asking whether PD-L1 is required for these processes — PD-L1 is the principal immune checkpoint ligand engaging PD-1 on activated T cells. Overexpression is useful for studying PD-L1 gain-of-function effects. For systematic PD-L1 biochemistry, the EDITGENE CD274 Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies and high-throughput rescue mutant screening. This product complements the parallel CD274 Knockouts in HeLa (imaging) and HCT 116 (colorectal context) for cross-background validation. Rescue with wild-type, PD-1-binding-deficient, or surface trafficking-deficient PD-L1 enables comprehensive structure-function studies. The knockout is a critical specificity tool for ⭐⭐⭐ pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, cemiplimab — the foundational class of cancer immunotherapy — and emerging next-generation PD-L1-targeted bispecifics, ADCs, and degraders.

Yes. PD-L1 rescue experiments in HEK293 are gold-standard for systematic biochemistry research: • Construct design: same considerations as PD-L1/HeLa rescue. • High-throughput PD-L1 mutation screening: HEK293's high transfection efficiency supports systematic anti-PD-L1 antibody epitope mapping and PD-1-binding mutation analysis. • Therapy resistance studies: rescue with PD-L1 mutations conferring resistance to specific anti-PD-L1/anti-PD-1 antibodies for on-target validation. • Functional readout: rescue should restore PD-1 binding measured by PD-1-Fc binding assays. HEK293 transduces efficiently with lentivirus and is the gold-standard platform for PD-1/PD-L1 biochemistry.

The choice depends on whether you are studying CLEC12A (CD371, MICL)'s role as an inhibitory C-type lectin receptor or modeling its emerging functions as an AML therapy target. The Knockout line is the standard tool for asking whether CLEC12A is required for these processes — CLEC12A is a C-type lectin-like ITIM-containing inhibitory receptor expressed on myeloid cells (granulocytes, monocytes, DCs) and importantly on AML leukemic stem cells (LSCs); CLEC12A recognizes monosodium urate crystals released from dying cells as a damage-associated molecular pattern. Overexpression is useful for studying CLEC12A in heterologous expression contexts. For AML therapy research, the EDITGENE CLEC12A Knockout in HEK293 is uniquely valuable — CLEC12A is selectively expressed on AML leukemic stem cells with minimal expression on normal hematopoietic stem cells, making it one of the most validated AML-specific therapy targets. Rescue with wild-type or ITIM-mutant CLEC12A enables structure-function studies. The knockout is a critical specificity tool for ⭐ tepoditamab/MCLA-117 (anti-CLEC12A × CD3 bispecific T-cell engager, clinical development for AML), CLEC12A-targeted CAR-T cells, and emerging CLEC12A-targeted AML therapeutics — CLEC12A may enable AML therapy with reduced HSC toxicity.

Yes. CLEC12A rescue experiments require attention to ITIM signaling architecture: • Construct design: use a codon-modified CLEC12A sequence with a small intracellular C-terminal tag (FLAG, HA). CLEC12A has extracellular C-type lectin-like domain, transmembrane span, and intracellular ITIM (immunoreceptor tyrosine-based inhibitory motif) — preserve all elements. • Surface localization validation: confirm plasma membrane localization before functional assays. • ITIM-mutant rescue: tyrosine-to-phenylalanine mutation in the ITIM (Y7F) abolishes SHP1/SHP2 recruitment. • Functional readout: rescue should restore inhibitory signaling and anti-CLEC12A bispecific/CAR-T compound binding. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for CLEC12A-targeted compound testing.

The choice depends on whether you are studying CD70's role as a TNF family ligand or modeling its emerging applications as an AML and renal cell carcinoma therapy target. The Knockout line is the standard tool for asking whether CD70 is required for these processes — CD70 is a type II transmembrane TNF family ligand that binds CD27 (TNFRSF7) on T cells, B cells, and NK cells, driving co-stimulation and survival signaling; CD70 is highly expressed on activated immune cells, but importantly is aberrantly expressed on AML, lymphoma, and renal cell carcinoma. Overexpression is useful for studying CD70 in heterologous expression contexts. For cancer immunotherapy research, the EDITGENE CD70 Knockout in HEK293 is uniquely valuable — CD70 is one of the most clinically advanced AML/RCC therapy targets. Rescue with wild-type CD70 is the standard specificity control. The knockout is a critical specificity tool for ⭐ cusatuzumab (ARGX-110, anti-CD70 antibody in clinical development for AML — has shown promising activity), allogeneic CD70-CAR-T cells (CTX130 for RCC and T-cell lymphoma), CD70-ADCs (SGN-CD70A, MDX-1203), and emerging CD70-targeted approaches — CD70 is particularly attractive because of its restricted normal-tissue expression.

Yes. CD70 rescue experiments require attention to type II TNF family ligand architecture: • Construct design: use a codon-modified CD70 sequence with a small intracellular N-terminal tag (FLAG, HA) — CD70 is a type II transmembrane TNF family ligand with intracellular N-terminus and extracellular C-terminal TNF homology domain; N-terminal tag preserves extracellular ligand region. • Surface localization validation: confirm plasma membrane CD70 by cell surface staining before anti-CD70 compound testing. • Trimerization considerations: TNF family ligands function as trimers — rescue should preserve trimerization-competent CD70. • Functional readout: rescue should restore CD27-binding activity and anti-CD70 antibody/CAR-T/ADC compound binding. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic CD70-targeted therapy validation.

The choice depends on whether you are studying CEACAM5 (carcinoembryonic antigen 5, CEA)'s role as the classical CEA tumor marker or modeling its applications in CEACAM5-targeted cancer therapy. The Knockout line is the standard tool for asking whether CEACAM5 is required for these processes — CEACAM5 is a GPI-anchored cell surface glycoprotein highly expressed on epithelial cancers (colorectal, lung, gastric, pancreatic, breast) with low normal-tissue expression except colon epithelium; CEACAM5 is the classical 'CEA' tumor marker for monitoring colorectal cancer recurrence by serum measurement, and is an emerging cancer therapy target. Overexpression is useful for studying CEACAM5 gain-of-function effects. For cancer therapy research, the EDITGENE CEACAM5 Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies of CEA and serves as a critical specificity control for CEACAM5-targeted compound development. Other CEACAM family member (CEACAM1, CEACAM6, CEACAM7, CEACAM8) expression analysis aids interpretation given some antibody cross-reactivity. Rescue with wild-type or GPI-anchor-deficient CEACAM5 enables structure-function studies. The knockout is a critical specificity tool for ⭐ tusamitamab ravtansine (anti-CEACAM5 ADC, in Phase III clinical development for NSCLC), CEACAM5-targeted CAR-T cells, anti-CEACAM5 × CD3 bispecific antibodies (cibisatamab/CEA-TCB), and labetuzumab govitecan (anti-CEACAM5 ADC) — CEACAM5 is one of the most validated solid tumor surface antigens for targeted therapy development.

Yes. CEACAM5 rescue experiments require attention to GPI anchor processing: • Construct design: use a codon-modified CEACAM5 sequence with a small N-terminal tag (FLAG, HA) — CEACAM5 is a GPI-anchored protein with C-terminal GPI signal sequence cleaved during processing; C-terminal tags are removed during GPI attachment. • Surface localization validation: confirm plasma membrane GPI-anchored expression by cell surface staining. • GPI-attachment-deficient rescue: C-terminal GPI signal mutations abolish GPI processing, generating secreted CEACAM5. • Domain-specific rescue: CEACAM5 has multiple Ig-like extracellular domains; specific tumor-targeting antibody epitopes can be analyzed by domain truncation. • Functional readout: rescue should restore CEACAM5-targeted compound (tusamitamab ravtansine, cibisatamab, labetuzumab govitecan) cellular binding. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic CEACAM5-targeted compound development.

The choice depends on whether you are studying CA9 (carbonic anhydrase IX, CAIX)'s role as the principal hypoxia-induced carbonic anhydrase or modeling its applications as a renal cell carcinoma biomarker and therapy target. The Knockout line is the standard tool for asking whether CA9 is required for these processes — CA9 is a HIF1α-induced surface carbonic anhydrase that catalyzes CO₂ + H₂O ↔ HCO₃⁻ + H⁺ at the extracellular face, acidifying the tumor microenvironment and supporting cancer cell pH regulation under hypoxia; CA9 is uniquely restricted to gastric epithelium under normal conditions but dramatically upregulated in many hypoxic tumors. Overexpression is useful for studying CA9 gain-of-function effects. For cancer hypoxia research, the EDITGENE CA9 Knockout in HEK293 is uniquely valuable — CA9 is one of the most validated hypoxic tumor biomarkers and emerging cancer therapy targets, particularly in renal cell carcinoma (ccRCC has near-universal CA9 expression due to VHL loss-induced HIF1α stabilization). Rescue with wild-type or catalytically-dead CA9 enables structure-function studies. The knockout is a critical specificity tool for ⭐ girentuximab (anti-CA9 antibody) — recently completed Phase III for ccRCC, ⁸⁹Zr-girentuximab PET imaging (CA9-targeted ccRCC imaging), Lu-177-girentuximab radioligand therapy candidates, anti-CA9 CAR-T cells, and CA9-selective inhibitors (acetazolamide is non-selective; selective CA9 inhibitors SLC-0111 in clinical development).

Yes. CA9 rescue experiments require attention to membrane targeting and dual-domain architecture: • Construct design: use a codon-modified CA9 sequence with a small intracellular C-terminal tag (FLAG, HA). CA9 has N-terminal proteoglycan-like (PG) domain, central catalytic carbonic anhydrase domain, single transmembrane span, and short cytoplasmic tail — preserve membrane topology. • Surface localization validation: confirm plasma membrane CA9 by cell surface staining before girentuximab/SLC-0111 testing. • Catalytically-dead rescue: active site zinc-binding histidine mutations abolish carbonic anhydrase activity. • Functional readout: rescue should restore CA9 enzymatic activity and girentuximab binding. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CD74 (invariant chain, Ii, MHC class II invariant chain)'s role as the MHC class II chaperone or modeling its functions as the macrophage migration inhibitory factor (MIF) receptor and emerging cancer immunotherapy applications. The Knockout line is the standard tool for asking whether CD74 is required for these processes — CD74 has dual functions: (1) as the MHC class II invariant chain in APCs, where the CD74 CLIP region occupies the MHC II peptide groove during ER-to-MIIC trafficking; (2) as the cell surface MIF receptor (with CD44 co-receptor) that mediates pro-inflammatory and pro-survival MIF signaling in macrophages, B cells, and cancer cells. Overexpression is useful for studying CD74 gain-of-function effects. For immunology and cancer therapy research, the EDITGENE CD74 Knockout in HEK293 is highly valuable — HEK293 supports systematic structure-function studies of CD74. Rescue with wild-type or CLIP-deficient CD74 enables structure-function studies. The knockout is a critical specificity tool for ⭐ milatuzumab (anti-CD74 antibody in clinical development for hematologic malignancies), STRO-001 (CD74-ADC), ISB 1442 (CD74×CD47 bispecific), MIF-targeted therapies (ibudilast affects MIF signaling), and emerging CD74-targeted approaches in B-cell lymphomas and inflammatory diseases.

Yes. CD74 rescue experiments require attention to type II membrane topology and dual functions: • Construct design: use a codon-modified CD74 sequence with a small intracellular N-terminal tag (FLAG, HA) — CD74 is a type II transmembrane protein with intracellular N-terminus and extracellular C-terminus (with CLIP and trimerization regions); N-terminal tag preserves extracellular regions. • Surface localization validation: confirm plasma membrane CD74 by cell surface staining for MIF receptor assays. • CLIP-deficient rescue: CLIP region mutations affect MHC II peptide loading but may preserve MIF receptor function — useful for separating CD74's two functions. • Functional readout: rescue should restore MHC II maturation (in APC-relevant contexts) and MIF-induced signaling. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CCR5 (CC chemokine receptor 5, CD195)'s role as the principal HIV co-receptor or modeling its functions in T cell trafficking and HIV-cure strategies. The Knockout line is the standard tool for asking whether CCR5 is required for these processes — CCR5 is a Gαi-coupled seven-transmembrane GPCR activated by CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES), expressed on effector/memory T cells, monocytes, macrophages, and DCs; CCR5 is the principal co-receptor for R5-tropic HIV-1 strains (which represent ~90% of new infections), and the CCR5Δ32 homozygous mutation confers HIV resistance — this is the basis of the Berlin, London, and Düsseldorf patients (cured of HIV by CCR5Δ32 allogeneic HSC transplantation). Overexpression is useful for studying CCR5 in heterologous expression contexts. For HIV research, the EDITGENE CCR5 Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies. Rescue with wild-type or signaling-deficient CCR5 enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐ maraviroc (Selzentry, FDA-approved 2007 CCR5 antagonist for HIV-1), leronlimab (PRO 140, anti-CCR5 antibody in development), CCR5-modifying gene therapy approaches for HIV cure (sangamo's SB-728, allogeneic CCR5Δ32 HSCT, CRISPR-based CCR5 disruption), and emerging CCR5-targeted approaches in cancer (CCR5 on Tregs and TAMs).

Yes. CCR5 rescue experiments are well-established for HIV co-receptor research: • Construct design: use a codon-modified CCR5 sequence with a small intracellular C-terminal tag (FLAG, HA). CCR5 is a seven-transmembrane Gαi-coupled GPCR with N-terminal sulfated tyrosines (HIV gp120 binding) — preserve all elements. • Surface localization validation: confirm plasma membrane localization by cell surface staining before HIV envelope binding studies. • CCR5Δ32 rescue: rescue with CCR5Δ32 (frameshift mutation, no surface expression) compared to wild-type recapitulates the HIV-resistant phenotype. • Maraviroc-resistant rescue: gp120-binding-pocket mutations can confer resistance for on-target validation. • Functional readout: rescue should restore R5-tropic HIV envelope-mediated entry and maraviroc sensitivity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for HIV research.

The choice depends on whether you are studying CDK4's role as the canonical G1/S CDK or modeling CDK4/6 inhibitor pharmacology and breast cancer biology. The Knockout line is the standard tool for asking whether CDK4 is required for these processes — CDK4 partners with D-type cyclins to phosphorylate RB1; CDK4 is the principal CDK4/6 family member in many epithelial contexts, with critical roles in breast, pancreatic, and other cancers. Overexpression is useful for studying CDK4 gain-of-function effects. Important consideration: CDK4 and CDK6 paralog dissection is essential — combined CDK4+CDK6 loss is typically required to fully arrest in G1. This product complements the parallel CDK6 Knockout in HEK293 (also available) for systematic CDK4/6 paralog studies. Rescue with wild-type or kinase-dead CDK4 is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐⭐ palbociclib, ribociclib, abemaciclib FDA-approved breast cancer drugs, the new CDK4-selective inhibitor PF-07220060 (in development), and emerging CDK4-targeted approaches.